Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for acute migraine treatment in adults unsuitable for triptan use
2024-513269-37-00Phase 4Completed
- Sponsor
- Pfizer
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 4, randomised, double-blind trial in migraine comparing Vydura with Placebo (2 arms). Primary endpoint: Headache pain intensity of none or mild at 2 hours postdose. Started Mar 2023; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2024-513269-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513269-37-00.